Mayinglong Pharmaceutical Group Company Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
2,544
- Stock Symbol
-
600993
- Investments
-
8
- Share Price
-
$3.95
- (As of Friday Closing)
Mayinglong Pharmaceutical Group Company General Information
Description
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
Contact Information
Website
www.mayinglong.cnCorporate Office
- Number 100 Zhoujiawan
- Nanhu Lake Wuchang District
- Wuhan, Hubei 430064
- China
Corporate Office
- Number 100 Zhoujiawan
- Nanhu Lake Wuchang District
- Wuhan, Hubei 430064
- China
Mayinglong Pharmaceutical Group Company Stock Performance
As of 20-Nov-2026, Mayinglong Pharmaceutical Group Company’s stock price is $3.95. Its current market cap is $1.7B with 431M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.95 | $3.96 | $3.12 - $4.29 | $1.7B | 431M | 5.52M | $0.20 |
Mayinglong Pharmaceutical Group Company Financials Summary
As of 30-Sep-2026, Mayinglong Pharmaceutical Group Company has a trailing 12-month revenue of $579M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,111,328 | 1,380,023 | 1,180,241 | 1,164,569 |
| Revenue | 578,920 | 537,677 | 519,552 | 443,364 |
| EBITDA | 103,617 | 107,121 | 94,867 | 79,314 |
| Net Income | 86,299 | 80,860 | 73,597 | 62,651 |
| Total Assets | 842,441 | 776,972 | 709,845 | 681,309 |
| Total Debt | 10,635 | 14,168 | 32,084 | 38,413 |
Mayinglong Pharmaceutical Group Company Patents
Mayinglong Pharmaceutical Group Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026119097-A1 | External-use traditional chinese medicine composition for treating anorectal diseases, traditional chinese medicine formulation, preparation method therefor, and use thereof | Pending | 02-Dec-2024 | ||
| US-20260139220-A1 | Lacticaseibacillus rhamnosus mbp01 and combination thereof for preventing and treating irritable bowel syndrome | Pending | 15-Nov-2024 | ||
| WO-2026103131-A1 | Lactobacillus rhamnosus mbp01 for preventing and treating irritable bowel syndrome and composition thereof | Pending | 15-Nov-2024 | ||
| WO-2026061469-A1 | Heteroaromatic amine compound, pharmaceutical composition thereof and use thereof | Pending | 19-Sep-2024 | ||
| US-20140087010-A1 | Preparation method for extractive of jinxuan hemorrhoid washing powder botanicals | Active | 08-Mar-2011 | A61K36/538 |
Mayinglong Pharmaceutical Group Company Signals
Mayinglong Pharmaceutical Group Company Investments (8)
Mayinglong Pharmaceutical Group Company’s most recent deal was a Secondary Transaction - Private with Mayinglong Changqing Hospital. The deal was made on 20-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Mayinglong Changqing Hospital | 20-Oct-2022 | Secondary Transaction - Private | Hospitals/Inpatient Services | ||
| Health Medicare | 01-Sep-2020 | Corporate | Pharmaceuticals | ||
| Okay Pharmaceutical | 23-Dec-2016 | Corporate | Specialty Chemicals | ||
| Jilang Biotechnology | 25-Feb-2016 | Early Stage VC | Diagnostic Equipment | ||
| Leimai Technology | 25-May-2015 | Later Stage VC | Therapeutic Devices |
Mayinglong Pharmaceutical Group Company ESG
Risk Overview
Risk Rating
Updated December, 31, 2023
30.88 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Mayinglong Pharmaceutical Group Company Exits (1)
Mayinglong Pharmaceutical Group Company’s most recent exit was on 28-Jan-2000 from Dafu Pharmaceutical. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Dafu Pharmaceutical | 28-Jan-2000 | Completed |
|
Mayinglong Pharmaceutical Group Company Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Mayinglong Changqing Hospital | Beijing, China | 2009 |
Mayinglong Pharmaceutical Group Company FAQs
-
When was Mayinglong Pharmaceutical Group Company founded?
Mayinglong Pharmaceutical Group Company was founded in 1994.
-
Where is Mayinglong Pharmaceutical Group Company headquartered?
Mayinglong Pharmaceutical Group Company is headquartered in Wuhan, China.
-
What is the size of Mayinglong Pharmaceutical Group Company?
Mayinglong Pharmaceutical Group Company has 2,544 total employees.
-
What industry is Mayinglong Pharmaceutical Group Company in?
Mayinglong Pharmaceutical Group Company’s primary industry is Pharmaceuticals.
-
Is Mayinglong Pharmaceutical Group Company a private or public company?
Mayinglong Pharmaceutical Group Company is a Public company.
-
What is Mayinglong Pharmaceutical Group Company’s stock symbol?
The ticker symbol for Mayinglong Pharmaceutical Group Company is 600993.
-
What is the current stock price of Mayinglong Pharmaceutical Group Company?
As of 20-Nov-2026 the stock price of Mayinglong Pharmaceutical Group Company is $3.95.
-
What is the current market cap of Mayinglong Pharmaceutical Group Company?
The current market capitalization of Mayinglong Pharmaceutical Group Company is $1.7B.
-
What is Mayinglong Pharmaceutical Group Company’s current revenue?
The trailing twelve month revenue for Mayinglong Pharmaceutical Group Company is $579M.
-
What is Mayinglong Pharmaceutical Group Company’s annual earnings per share (EPS)?
Mayinglong Pharmaceutical Group Company’s EPS for 12 months was $0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process